Líffræðifélag Íslands - biologia.is
Líffræðiráðstefnan 2021

Erindi/veggspjald / Talk/poster V58

Can heterologous prime-boost strategy improve mucosal and systemic immune response in neonates?

Höfundar / Authors: Poorya Foroutan Pajoohian (1,2), Jenny Lorena Molina Estupiñan (1,2), Auður Anna Aradottir Pind (1,2), Dennis Christensen (3), Jan Holmgren (4), Thorunn A. Olafsdottir (5), Ingileif Jonsdottir (1,2) , Stefania P. Bjarnarson (1,2)

Starfsvettvangur / Affiliations: 1Faculty of Medicine, School of Health Sciences, University of Iceland, 2Department of Immunology, Landspitali, the National University Hospital of Iceland, 3Statens Serum Institute, Copenhagen, Denmark, 4University of Gothenburg, Dept. Microbiology and Immunology, Institute of Biomedicine, Sahlgrenska Academy, and University of Gothenburg Vaccine Research Institute (GUVAX), Sweden, 5deCODE genetics, Reykjavík, Iceland.

Kynnir / Presenter: Poorya Foroutan Pajoohian

Most pathogens enter the body through the mucosal surfaces. Immunoglobulin A (IgA) is a key element in this first line of defense and IgG is critical for killing of most bacteria. The aim of the study is to establish immunization protocol that induces robust mucosal and systemic antibodies and antibody secreting cells (AbSC) in neonates that are susceptible to infections. We immunized neonatal mice (7 day old) with 0.5µg Pnc1-CRM197 pneumococcal conjugate vaccine using a heterologous subcutaneous (s.c.) and intranasal (i.n.) prime-boost strategy. The adjuvant CAF01 that induces IgA and activates CD4+ T cells after immunization was used for s.c. priming and the mucosal adjuvant mmCT for i.n. booster 16 days later and compared with homologous s.c. priming with/without CAF01 and s.c. Pn1-CRM197 booster. Preliminary results show that Pn1-specific IgA level was higher 7-35 days after i.n. booster with Pn1-CRM197 + 1µg mmCT than after s.c. Pn1-CRM197 booster but serum Pn1-specific IgG level was lower after i.n. than s.c. booster. The frequency of Pn1-specific IgA AbSC in spleen was higher 35 days after i.n. than s.c. booster, but IgG AbSC in spleen were significantly lower after i.n. than s.c. booster. IgG and IgA AbSC in bone marrow were similar. Altogether, the results suggest that this heterologous prime-boost strategy for Pn1-CRM197 with CAF01 and mmCT enhances production and persistence of Pn1-specific IgA, whereas it has no benefits for systemic IgG response in neonates.